Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and homoharringtonine with intensive chemotherapy for core-binding factor acute myeloid leukemia
ChiCTR1900022613Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dasatinib and homoharringtonine in acute myeloid leukemia (AML) (2 arms), sponsored by Ruijin Hospital. Primary endpoints: Event-free survival, Overall survival and 1 more. Planned start May 2019; status: not yet recruiting.
02
Drugs
dasatinibhomoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1900022613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022613.